1887
Volume 2025, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Pulmonary fibrosis is characterized by excessive matrix formation, which destroys typical lung architecture and increases the chances of comorbidity. It is essential to look into potential serum indicators for the early identification of individuals who may develop such severe fibrotic consequences since there is currently no specific marker for the early diagnosis of post-COVID-19 pulmonary fibrosis. The study is aimed at examining potential serum markers that could be used for early detection of pulmonary fibrosis in patients with COVID-19.

It is a cross-sectional retrospective observational study that included male ( = 26) and female ( = 10) patients who were confirmed positive for COVID-19 using the Reverse transcription polymerase chain reaction (RTPCR) test. Various hematological parameters, such as platelet count, white blood cell count (WBC count), platelet-to-lymphocyte ratio (PLR), white blood cell count to mean platelet volume ratio (WMR), red cell distribution width (RDW), plateletcrit (PCT), mean platelet volume (MPV), platelet distribution width (PDW), serum ferritin level, and CT severity scores (CT-SSs) were recorded. The association between hematological parameters, serum ferritin level, and CT-SS was assessed by the Pearson correlation test using the GraphPad Prism software (version 10). < 0.05 was considered statistically significant.

The descriptive analysis revealed no significant correlation between platelet count ( = 0.1610, = 0.3483), WBC count ( = −0.1381, = 0.4217), PLR ( = 0.2262, = 0.1847), WMR ( = −0.1093, = 0.5258), RDW ( = 0.05982, = 0.7289), PCT ( = −0.059, = 0.752), MPV ( = 0.046, = 0.788), and PDW ( = −0.06, = 0.699) with CT-SS. However, a significant positive correlation was observed between CT-SS and serum ferritin levels in COVID-19 patients ( = 0.5452, = 0.0006).

As there was a significant positive correlation between serum ferritin level and CT-SS, the serum ferritin level could be considered as a simple and cost-effective biomarker for predicting the development of lung fibrosis in long COVID-19 conditions after controlling the confounders.

© 2025 Ojha, Bhasin, Agni, Gowda, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.44
2025-06-09
2025-07-17
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/2/qmj.2025.44.html?itemId=/content/journals/10.5339/qmj.2025.44&mimeType=html&fmt=ahah

References

  1. COVID-19 coronavirus pandemic. Available from: https://www.worldometers.info/coronavirus/
  2. Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021; 12:1–24.
    [Google Scholar]
  3. Palladino M. Complete blood count alterations in covid-19 patients: a narrative review. Biochem Medica. 2021; 31:(3)1–13.
    [Google Scholar]
  4. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al.. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020; 27:(6)992–1000.
    [Google Scholar]
  5. Yan L, Zhang HT, Goncalves J, Xiao Y, Wang M, Guo Y, et al.. An interpretable mortality prediction model for COVID-19 patients. Nat Mach Intell. 2020; 2:(5)283–8.
    [Google Scholar]
  6. Wang Y, Wang H, Zhang C, Zhang C, Yang H, Gao R, et al.. Lung fluid biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2019; 23:(1)1–15.
    [Google Scholar]
  7. Middleton EA, Rondina MT, Schwertz H, Zimmerman GA. Amicus or adversary revisited: platelets in acute lung injury & acute respiratory distress syndrome Elizabeth. Am J Respir Cell Mol Biol. 2007;(35824)1–59.
    [Google Scholar]
  8. Vasarmidi E, Tsitoura E, Spandidos D, Tzanakis N, Antoniou K. Pulmonary fibrosis in the aftermath of the Covid-19 era (review). Exp Ther Med. 2020; 20:2557–60.
    [Google Scholar]
  9. Xiang M, Wu X, Jing H, Liu L, Wang C, Wang Y, et al.. The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors. Front Immunol. 2022; 13:1–17.
    [Google Scholar]
  10. Fujii M, Hayakawa H, Urano T, Sato A, Chida K, Nakamura H, et al.. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res. 2000; 99:(2)111–7.
    [Google Scholar]
  11. Mahdavi-Zafarghandi R, Shakiba B, Keramati MR, Tavakkoli M. Platelet volume indices in patients with varicocele. Clin Exp Reprod Med. 2014; 41:(2)92–5.
    [Google Scholar]
  12. Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev. 2020; 19:102573.
    [Google Scholar]
  13. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017; 29:401–9.
    [Google Scholar]
  14. Pretorius E, Kell DB. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integr Biol. 2014; 6:486–510.
    [Google Scholar]
  15. Edeas M, Saleh J, Peyssonnaux C. Iron: innocent bystander or vicious culprit in COVID-19 pathogenesis?Int J Infect Dis. 2020; 97:303–5.
    [Google Scholar]
  16. Lipinski B, Pretorius E, Oberholzer HM, Van Der Spuy WJ. Iron enhances generation of fibrin fibers in human blood: implications for pathogenesis of stroke. Microsc Res Tech. 2012; 75:1185–90.
    [Google Scholar]
  17. Arosio P, Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med. 2002; 33:(4)457–63.
    [Google Scholar]
  18. Kurian SJ, Mathews SP, Paul A, Viswam SK, Nagri SK, Miraj SS, et al.. Association of serum ferritin with severity and clinical outcome in COVID-19 patients: an observational study in a tertiary healthcare facility. Clin Epidemiol Glob Health. 2023; 21:101295.
    [Google Scholar]
  19. Enomoto N, Oyama Y, Enomoto Y, Mikamo M, Karayama M, Hozumi H, et al.. Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. Clin Respir J. 2018; 12:(8)2378–89.
    [Google Scholar]
  20. Chong DL, Mikolasch TA, Sahota J, Rebeyrol C, Garthwaite HS, Booth HL, et al.. Investigating the role of platelets and platelet-derived transforming growth factor-β in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2023; 325:(4)L487–99.
    [Google Scholar]
  21. Kommoss FK, Schwab C, Tavernar L, Schreck J, Wagner WL, Merle U, et al.. The pathology of severe COVID-19-related lung damage: mechanistic and therapeutic implications. Deutsch Ärztebl Int. 2020; 117:(29-30)500.
    [Google Scholar]
  22. Thille AW, Esteban A, Fernández-Segoviano P, Rodriguez JM, Aramburu JA, Vargas-Errázuriz P, et al.. Chronology of histological lesions in acute respiratory distress syndrome with diff use alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med. 2013; 1:(5)395–401.
    [Google Scholar]
  23. Makhlouf HA, Sadek SH, Nafady AAH. Platelet function in diabetic and nondiabetic patients with chronic obstructive pulmonary disease: a case control study. Clin Respir J. 2018; 12:(1)48–56.
    [Google Scholar]
  24. Quispe-Pari JF, Gonzales-Zamora JA, Munive-Dionisio J, Castro-Contreras C, Villar-Astete A, Kong-Paravicino C, et al.. Mean platelet volume as a predictor of COVID-19 severity: a prospective cohort study in the highlands of Peru. Diseases. 2022; 10:(2)22.
    [Google Scholar]
  25. Ulucan S¸, Keser A, Kaya Z, Katlandur H, Özdil H, Bilgi M, et al.. Association between PDW and long term major adverse cardiac events in patients with acute coronary syndrome. Hear Lung Circ. 2016; 25:(1)29–34.
    [Google Scholar]
  26. Tertemiz KC, Alpaydin AO, Sevinc C, Ellidokuz H, Acara AC, Cimrin A. Could “red cell distribution width” predict COPD severity?Revista Portuguesa de Pneumologia (English Edition). 2016; 22:(4)196–201.
    [Google Scholar]
  27. Aksu Y, Uslu AU, Tarhan G, Karagülle M. Predictive value of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in evaluating both lung involvement and severity of patients with coronavirus disease 2019. Saudi Med J. 2021; 42:(11)1223–8.
    [Google Scholar]
  28. Crooks MG, Fahim A, Naseem KM, Morice AH, Hart SP. Increased platelet reactivity in idiopathic pulmonary fibrosis is mediated by a plasma factor. PLoS One. 2014; 9:(10)1–8.
    [Google Scholar]
  29. Aktas A. Is mean platelet volume useful for predicting the prognosis of COVID-19 diagnosed patients?Int J Res Stud Med Heal Sci. 2020; 5:(7)8–11.
    [Google Scholar]
  30. Ntolios P, Papanas N, Nena E, Boglou P, Koulelidis A, Tzouvelekis A, et al.. Mean platelet volume as a surrogate marker for platelet activation in patients with idiopathic pulmonary fibrosis. Clin Appl Thromb. 2016; 22:(4)346–50.
    [Google Scholar]
  31. Patil S, Gondhali G, Acharya A. Role of ferritin as “core marker” in the assessment of severity, response to therapy and predicting outcome in COVID-19 pneumonia: a large, two-center, prospective, observational study of 1000 cases in tertiary care setting in India. Indian J Respir Care. 2022; 11:(3)253–60.
    [Google Scholar]
/content/journals/10.5339/qmj.2025.44
Loading
Serum ferritin as a predictive marker of pulmonary fibrosis in post-COVID-19
Qatar Medical Journal 2025, 44 (2025); https://doi.org/10.5339/qmj.2025.44
/content/journals/10.5339/qmj.2025.44
/content/journals/10.5339/qmj.2025.44
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): COVID-19, CT severity score, Ferritin, Platelet Distribution Width, Plateletcrit and Red cell Distribution Width

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error